Leadiant Biosciences S.A;The UAB Research Foundation
发明人:
申请号：
EP16709148.7
公开号：
EP3265075B1
申请日:
2016.03.03
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
The present invention relates to roneparstat for use in a combined therapy for the treatment of multiple myeloma. In particular it has unexpectedly been found that the combined use of roneparstat with a proteasome inhibitor, in particular selected between bortezomib and carfilzomib improve efficacy in decreasing the overall tumor burden, especially showing synergism, with respect to the administration of each active ingredient alone.
